Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Tam, CS; Quach, H; Nicol, A; Badoux, X; Rose, H; Prince, HM; Leahy, MF; Eek, R; Wickham, N; Patil, SS; Huang, J; Prathikanti, R; Cohen, A; Elstrom, R; Reed, W; Schneider, J; Flinn, IW

Tam, CS (corresponding author), Peter MacCallum Canc Ctr, 305 Grattan St, Melbourne, Vic 3050, Australia.

BLOOD ADVANCES, 2020; 4 (19): 4802

Abstract

Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducte......

Full Text Link